<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39380724</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2468-0427</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Infectious Disease Modelling</Title><ISOAbbreviation>Infect Dis Model</ISOAbbreviation></Journal><ArticleTitle>Planning and adjusting the COVID-19 booster vaccination campaign to reduce disease burden.</ArticleTitle><Pagination><StartPage>150</StartPage><EndPage>162</EndPage><MedlinePgn>150-162</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.idm.2024.09.002</ELocationID><Abstract><AbstractText>As public health policies shifted in 2023 from emergency response to long-term COVID-19 disease management, immunization programs started to face the challenge of formulating routine booster campaigns in a still highly uncertain seasonal behavior of the COVID-19 epidemic. Mathematical models assessing past booster campaigns and integrating knowledge on waning of immunity can help better inform current and future vaccination programs. Focusing on the first booster campaign in the 2021/2022 winter in France, we used a multi-strain age-stratified transmission model to assess the effectiveness of the observed booster vaccination in controlling the succession of Delta, Omicron BA.1 and BA.2 waves. We explored counterfactual scenarios altering the eligibility criteria and inter-dose delay. Our study showed that the success of the immunization program in curtailing the Omicron BA.1 and BA.2 waves was largely dependent on the inclusion of adults among the eligible groups, and was highly sensitive to the inter-dose delay, which was changed over time. Shortening or prolonging this delay, even by only one month, would have required substantial social distancing interventions to curtail the hospitalization peak. Also, the time window for adjusting the delay was very short. Our findings highlight the importance of readiness and adaptation in the formulation of routine booster campaign in the current level of epidemiological uncertainty.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Di Domenico</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Yair</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Faculty of Data and Decisions Science, Technion-Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colizza</LastName><ForeName>Vittoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sorbonne Université, INSERM, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Georgetown University, WA, District of Columbia, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Infect Dis Model</MedlineTA><NlmUniqueID>101692406</NlmUniqueID><ISSNLinking>2468-0427</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Age-structured model</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Immunity waning</Keyword><Keyword MajorTopicYN="N">Inter-dose delay</Keyword><Keyword MajorTopicYN="N">Vaccination strategies</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>10</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>9</Day><Hour>4</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39380724</ArticleId><ArticleId IdType="pmc">PMC11459620</ArticleId><ArticleId IdType="doi">10.1016/j.idm.2024.09.002</ArticleId><ArticleId IdType="pii">S2468-0427(24)00101-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Hasan M.R., Coyle P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A., Al-Romaihi H.E.…Abu-Raddad L.J. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. New England Journal of Medicine. 2022;387(17):1620–1622. doi: 10.1056/NEJMc2209306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209306</ArticleId><ArticleId IdType="pmc">PMC9559315</ArticleId><ArticleId IdType="pubmed">36198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Tang P., Hasan M.R., Yassine H.M., Al-Khatib H.A., Smatti M.K., Coyle P., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A.…Abu-Raddad L.J. Effects of previous infection and vaccination on symptomatic omicron infections. New England Journal of Medicine. 2022 doi: 10.1056/NEJMoa2203965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2203965</ArticleId><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H.N., Chemaitelly H., Hasan M.R., Ayoub H.H., Qassim S., AlMukdad S., Coyle P., Yassine H.M., Al-Khatib H.A., Benslimane F.M., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G.…Abu-Raddad L.J. Protection against the omicron variant from previous SARS-CoV-2 infection. New England Journal of Medicine. 2022 doi: 10.1056/NEJMc2200133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2200133</ArticleId><ArticleId IdType="pmc">PMC8849180</ArticleId><ArticleId IdType="pubmed">35139269</ArticleId></ArticleIdList></Reference><Reference><Citation>Amir O., Goldberg Y., Mandel M., Bar-On Y.M., Bodenheimer O., Freedman L., Alroy-Preis S., Ash N., Huppert A., Milo R. Protection against Omicron BA.1/BA.2 severe disease 0-7 months after BNT162b2 booster. Communications Biology. 2023;6(1):315. doi: 10.1038/s42003-023-04669-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04669-6</ArticleId><ArticleId IdType="pmc">PMC10035472</ArticleId><ArticleId IdType="pubmed">36959496</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard R.C., Davies N.G., Jit M., Edmunds W.J. Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era. Nature Communications. 2022;13(1):4879. doi: 10.1038/s41467-022-32404-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32404-y</ArticleId><ArticleId IdType="pmc">PMC9389516</ArticleId><ArticleId IdType="pubmed">35986002</ArticleId></ArticleIdList></Reference><Reference><Citation>Barreiro N.L., Govezensky T., Ventura C.I., Núñez M., Bolcatto P.G., Barrio R.A. Modelling the interplay of SARS-CoV-2 variants in the United Kingdom. Scientific Reports. 2022;12(1) doi: 10.1038/s41598-022-16147-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-16147-w</ArticleId><ArticleId IdType="pmc">PMC9296900</ArticleId><ArticleId IdType="pubmed">35859100</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard J., Taisne B., Figoni J., Mailles A., Durand J., Fayad M., Josset L., Maisa A., Werf S. van der, Châtelet I. P. du, Bernard-Stoecklin S. Impact of the omicron variant on SARS-CoV-2 reinfections in France, March 2021 to february 2022. Euro Surveillance. 2022;27(13) doi: 10.2807/1560-7917.ES.2022.27.13.2200247.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.13.2200247</ArticleId><ArticleId IdType="pmc">PMC8973013</ArticleId><ArticleId IdType="pubmed">35362406</ArticleId></ArticleIdList></Reference><Reference><Citation>Béraud G., Kazmercziak S., Beutels P., Levy-Bruhl D., Lenne X., Mielcarek N., Yazdanpanah Y., Boëlle P.-Y., Hens N., Dervaux B. The French connection: The first large population-based contact survey in France relevant for the spread of infectious diseases. PLoS One. 2015;10(7) doi: 10.1371/journal.pone.0133203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0133203</ArticleId><ArticleId IdType="pmc">PMC4503306</ArticleId><ArticleId IdType="pubmed">26176549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N., Ware H., Ma X., Li Z., Hosseini R., Cao C., Selemon A., Whelan M., Premji Z., Issa H., Cheng B., Raddad L.J.A., Buckeridge D.L., Kerkhove M.D.V., Piechotta V., Higdon M.M., Wilder-Smith A., Bergeri I., Feikin D.R.…Subissi L. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression. The Lancet Infectious Diseases. 2023 doi: 10.1016/S1473-3099(22)00801-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00801-5</ArticleId><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Borremans B., Gamble A., Prager K., Helman S.K., McClain A.M., Cox C., Savage V., Lloyd-Smith J.O. Quantifying antibody kinetics and RNA detection during early-phase SARS-CoV-2 infection by time since symptom onset. Elife. 2020;9 doi: 10.7554/eLife.60122.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.60122</ArticleId><ArticleId IdType="pmc">PMC7508557</ArticleId><ArticleId IdType="pubmed">32894217</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosetti P., Kiem C.T., Andronico A., Paireau J., Levy-Bruhl D., Alter L., Fontanet A., Cauchemez S. Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: Application to France in the winter 2021/22. Euro Surveillance. 2022;27(1) doi: 10.2807/1560-7917.ES.2022.27.1.2101125.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.1.2101125</ArticleId><ArticleId IdType="pmc">PMC8739339</ArticleId><ArticleId IdType="pubmed">34991778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bushman M., Kahn R., Taylor B.P., Lipsitch M., Hanage W.P. Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. Cell. 2021;184(26):6229–6242.e18. doi: 10.1016/j.cell.2021.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.026</ArticleId><ArticleId IdType="pmc">PMC8603072</ArticleId><ArticleId IdType="pubmed">34910927</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo S., Skowronski D.M., Brisson M., Barkati S., Sauvageau C., Brousseau N., Gilca R., Fafard J., Talbot D., Ouakki M., Gilca V., Carignan A., Deceuninck G., De Wals P., De Serres G. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: A test-negative case-control study. The Lancet Infectious Diseases. 2023;23(1):45–55. doi: 10.1016/S1473-3099(22)00578-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00578-3</ArticleId><ArticleId IdType="pmc">PMC9491856</ArticleId><ArticleId IdType="pubmed">36152671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., Coyle P., Tang P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Hasan M.R., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A., Al-Romaihi H.E.…Abu-Raddad L.J. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nature Communications. 2022;13(1):4675. doi: 10.1038/s41467-022-32363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32363-4</ArticleId><ArticleId IdType="pmc">PMC9362989</ArticleId><ArticleId IdType="pubmed">35945213</ArticleId></ArticleIdList></Reference><Reference><Citation>de Meijere G., Valdano E., Castellano C., Debin M., Kengne-Kuetche C., Turbelin C., Noël H., Weitz J.S., Paolotti D., Hermans L., Hens N., Colizza V. Attitudes towards booster, testing and isolation, and their impact on COVID-19 response in winter 2022/2023 in France, Belgium, and Italy: A cross-sectional survey and modelling study. The Lancet Regional Health – Europe. 2023;28 doi: 10.1016/j.lanepe.2023.100614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100614</ArticleId><ArticleId IdType="pmc">PMC10035813</ArticleId><ArticleId IdType="pubmed">37131863</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico L., Pullano G., Sabbatini C.E., Boëlle P.-Y., Colizza V. Impact of lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. BMC Medicine. 2020;18(1):240. doi: 10.1186/s12916-020-01698-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-020-01698-4</ArticleId><ArticleId IdType="pmc">PMC7391016</ArticleId><ArticleId IdType="pubmed">32727547</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico L., Pullano G., Sabbatini C.E., Boëlle P.-Y., Colizza V. Modelling safe protocols for reopening schools during the COVID-19 pandemic in France. Nature Communications. 2021;12(1):1073. doi: 10.1038/s41467-021-21249-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21249-6</ArticleId><ArticleId IdType="pmc">PMC7887250</ArticleId><ArticleId IdType="pubmed">33594076</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico L., Sabbatini C.E., Boëlle P.-Y., Poletto C., Crépey P., Paireau J., Cauchemez S., Beck F., Noel H., Lévy-Bruhl D., Colizza V. Adherence and sustainability of interventions informing optimal control against the COVID-19 pandemic. Communication and Medicine. 2021;1(1):1–13. doi: 10.1038/s43856-021-00057-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-021-00057-5</ArticleId><ArticleId IdType="pubmed">36759565</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Domenico L., Sabbatini C.E., Pullano G., Lévy-Bruhl D., Colizza V. Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France. Euro Surveillance. 2021;26(15) doi: 10.2807/1560-7917.ES.2021.26.15.2100272.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.15.2100272</ArticleId><ArticleId IdType="pmc">PMC8167415</ArticleId><ArticleId IdType="pubmed">33860748</ArticleId></ArticleIdList></Reference><Reference><Citation>ECDC  Interim public health considerations for COVID-19 vaccination roll-out during 2023. 2023. https://www.ecdc.europa.eu/en/publications-data/interim-public-health-considerations-covid-19-vaccination-roll-out-during-2023</Citation></Reference><Reference><Citation>Bleu France. Covid-19: Dose de rappel, pass sanitaire, ce qu’il faut retenir des annonces d'Olivier Véran. 2021. https://www.francebleu.frhttps://www.francebleu.fr/infos/sante-sciences/direct-covid-19-suivez-l-intervention-d-olivier-veran-1637769888</Citation></Reference><Reference><Citation>Franceinfo  Vaccin contre le Covid-19: Face à l’afflux de demandes, les créneaux pour la dose de rappel ne sont pas encore au rendez-vous. 2021. https://www.francetvinfo.fr/sante/maladie/coronavirus/vaccin/vaccin-contre-le-covid-19-face-a-l-afflux-de-demandes-les-creneaux-pour-la-dose-de-rappel-ne-sont-pas-encore-au-rendez-vous_4865531.html</Citation></Reference><Reference><Citation>French Ministry of Education  Calendrier scolaire. 2020. https://www.education.gouv.fr/calendrier-scolaire-100148</Citation></Reference><Reference><Citation>French Ministry of Education  Déconfinement phase 2: Point de situation au 28 mai. Ministère de l’Education Nationale et de la Jeunesse. 2020 https://www.education.gouv.fr/deconfinement-phase-2-point-de-situation-au-28-mai-303813</Citation></Reference><Reference><Citation>Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A.K., Abdelrahman T., Riccardo F., Stefanelli P., Martino A.D., Bella A.…Groups, on behalf of C. study Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: Data from seven EU/EEA countries. Euro Surveillance. 2021;26(16) doi: 10.2807/1560-7917.ES.2021.26.16.2100348. weeks 38/2020 to 10/2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.16.2100348</ArticleId><ArticleId IdType="pmc">PMC8063589</ArticleId><ArticleId IdType="pubmed">33890566</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavish N., Yaari R., Huppert A., Katriel G. Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence. Science Translational Medicine. 2022;14(647):eabn9836. doi: 10.1126/scitranslmed.abn9836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abn9836</ArticleId><ArticleId IdType="pmc">PMC9012104</ArticleId><ArticleId IdType="pubmed">35412326</ArticleId></ArticleIdList></Reference><Reference><Citation>Google  Community mobility report. COVID-19 community mobility report. 2020. https://www.google.com/covid19/mobility?hl=en</Citation></Reference><Reference><Citation>GOV.UK  JCVI statement on the adult COVID-19 booster vaccination programme and the omicron variant: 7 january 2022. 2022. https://www.gov.uk/government/publications/jcvi-statement-on-the-adult-covid-19-booster-vaccination-programme-and-the-omicron-variant/jcvi-statement-on-the-adult-covid-19-booster-vaccination-programme-and-the-omicron-variant-7-january-2022</Citation></Reference><Reference><Citation>Haute Autorité de Santé  Avis n° 2021.0061/AC/SEESP du 23 août 2021 du collège de la HAS relatif à la définition des populations à cibler par la campagne de rappel vaccinal chez les personnes ayant eu une primovaccination complète contre la Covid-19. 2021. https://www.has-sante.fr/jcms/p_3283044/fr/avis-n-2021-0061/ac/seesp-du-23-aout-2021-du-college-de-la-has-relatif-a-la-definition-des-populations-a-cibler-par-la-campagne-de-rappel-vaccinal-chez-les-personnes-ayant-eu-une-primovaccination-complete-contre-la-covid-19</Citation></Reference><Reference><Citation>Haute Autorité de Santé  Covid-19: Un rappel recommandé pour les 18 ans et plus dès 5 mois après la primo-vaccination. 2021. https://www.has-sante.fr/https://www.has-sante.fr/jcms/p_3301409/fr/covid-19-un-rappel-recommande-pour-les-18-ans-et-plus-des-5-mois-apres-la-primo-vaccination</Citation></Reference><Reference><Citation>Haute Autorité de Santé  Stratégie de vaccination contre la Covid-19 – Anticipation des scénarios possibles à l’automne 2022. 2022. https://www.has-sante.fr/jcms/p_3340479/fr/strategie-de-vaccination-contre-la-covid-19-anticipation-des-scenarios-possibles-a-l-automne-2022</Citation></Reference><Reference><Citation>Herrera-Esposito D., de los Campos G. Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infectious Diseases. 2022;22(1):311. doi: 10.1186/s12879-022-07262-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07262-0</ArticleId><ArticleId IdType="pmc">PMC8962942</ArticleId><ArticleId IdType="pubmed">35351016</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogan A.B., Wu S.L., Toor J., Olivera Mesa D., Doohan P., Watson O.J., Winskill P., Charles G., Barnsley G., Riley E.M., Khoury D.S., Ferguson N.M., Ghani A.C. Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study. PLoS Medicine. 2023;20(11) doi: 10.1371/journal.pmed.1004195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1004195</ArticleId><ArticleId IdType="pmc">PMC10715640</ArticleId><ArticleId IdType="pubmed">38016000</ArticleId></ArticleIdList></Reference><Reference><Citation>INSEE  Estimations de population—Pyramide des âges régionales et départementales. 2020. https://www.insee.fr/fr/statistiques/3696315</Citation></Reference><Reference><Citation>Jung S., Loo S.L., Howerton E., Contamin L., Smith C.P., Carcelén E.C., Yan K., Bents S.J., Levander J., Espino J., Lemaitre J.C., Sato K., McKee C.D., Hill A.L., Chinazzi M., Davis J.T., Mu K., Vespignani A., Rosenstrom E.T.…Lessler J. Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the U.S. COVID-19 Scenario Modeling Hub. medRxiv. 2023 doi: 10.1101/2023.10.26.23297581. 2023.10.26.23297581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.10.26.23297581</ArticleId><ArticleId IdType="pmc">PMC11062554</ArticleId><ArticleId IdType="pubmed">38630802</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn F., Bonander C., Moghaddassi M., Rasmussen M., Malmqvist U., Inghammar M., Björk J. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveillance. 2022;27(9) doi: 10.2807/1560-7917.ES.2022.27.9.2200121.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.9.2200121</ArticleId><ArticleId IdType="pmc">PMC8895467</ArticleId><ArticleId IdType="pubmed">35241215</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly S.L., Le Rutte E.A., Richter M., Penny M.A., Shattock A.J. COVID-19 vaccine booster strategies in light of emerging viral variants: Frequency, timing, and target groups. Infectious Disease and Therapy. 2022;11(5):2045–2061. doi: 10.1007/s40121-022-00683-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-022-00683-z</ArticleId><ArticleId IdType="pmc">PMC9464609</ArticleId><ArticleId IdType="pubmed">36094720</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Rutte E.A., Shattock A.J., Chitnis N., Kelly S.L., Penny M.A. Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden. Communication and Medicine. 2022;2(1):1–7. doi: 10.1038/s43856-022-00154-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43856-022-00154-z</ArticleId><ArticleId IdType="pmc">PMC9311342</ArticleId><ArticleId IdType="pubmed">35899148</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Vu S., Jones G., Anna F., Rose T., Richard J.-B., Bernard-Stoecklin S., Goyard S., Demeret C., Helynck O., Escriou N., Gransagne M., Petres S., Robin C., Monnet V., Perrin de Facci L., Ungeheuer M.-N., Léon L., Guillois Y., Filleul L.…Noel H. Prevalence of SARS-CoV-2 antibodies in France: Results from nationwide serological surveillance. Nature Communications. 2021;12:3025. doi: 10.1038/s41467-021-23233-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23233-6</ArticleId><ArticleId IdType="pmc">PMC8140151</ArticleId><ArticleId IdType="pubmed">34021152</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.-Y., Xu Y., Gu Y., Zeng D., Wheeler B., Young H., Sunny S.K., Moore Z. Effectiveness of bivalent boosters against severe omicron infection. New England Journal of Medicine. 2023;388(8):764–766. doi: 10.1056/NEJMc2215471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2215471</ArticleId><ArticleId IdType="pmc">PMC9933929</ArticleId><ArticleId IdType="pubmed">36734847</ArticleId></ArticleIdList></Reference><Reference><Citation>Maisa A., Spaccaferri G., Fournier L., Schaeffer J., Deniau J., Rolland P., Coignard B. First cases of Omicron in France are exhibiting mild symptoms, November 2021–January 2022. Infectious Diseases Now. 2022;52(3):160–164. doi: 10.1016/j.idnow.2022.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2022.02.003</ArticleId><ArticleId IdType="pmc">PMC9194534</ArticleId><ArticleId IdType="pubmed">35167979</ArticleId></ArticleIdList></Reference><Reference><Citation>Massonnaud C.R., Roux J., Colizza V., Crépey P. Evaluating COVID-19 booster vaccination strategies in a partially vaccinated population: A modeling study. Vaccines. 2022;10(3):479. doi: 10.3390/vaccines10030479.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10030479</ArticleId><ArticleId IdType="pmc">PMC8952850</ArticleId><ArticleId IdType="pubmed">35335111</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoli M., Domenico Di, Emergen L., Colizza V. Early assessment of the Omicron variant's presence and growth rate in regions of France. 2021. https://www.epicx-lab.com/uploads/9/6/9/4/9694133/inserm_omicron_frequency_20211222.pdf</Citation></Reference><Reference><Citation>Mazzoli M., Domenico Di, Emergen L., Colizza V. Assessment of the Omicron BA.2 sub-lineage presence and growth rate in regions of France. 2022. https://www.epicx-lab.com/uploads/9/6/9/4/9694133/inserm-covid-19-ba2_frequency-20220215.pdf</Citation></Reference><Reference><Citation>Mendes D., Chapman R., Aruffo E., Gal P., Nguyen J.L., Hamson L., Di Fusco M., Czudek C., Yang J. Public health impact of UK COVID-19 booster vaccination programs during Omicron predominance. Expert Review of Vaccines. 2023;22(1):90–103. doi: 10.1080/14760584.2023.2158816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2158816</ArticleId><ArticleId IdType="pubmed">36519401</ArticleId></ArticleIdList></Reference><Reference><Citation>Menegale F., Manica M., Zardini A., Guzzetta G., Marziano V., d'Andrea V., Trentini F., Ajelli M., Poletti P., Merler S. Evaluation of waning of SARS-CoV-2 vaccine–induced immunity: A systematic review and meta-analysis. JAMA Network Open. 2023;6(5) doi: 10.1001/jamanetworkopen.2023.10650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.10650</ArticleId><ArticleId IdType="pmc">PMC10157431</ArticleId><ArticleId IdType="pubmed">37133863</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministero della Salute  Norme, circolari e ordinanze dell’area Covid-19. 2021. https://www.salute.gov.it/portale/nuovocoronavirus/archivioNormativaNuovoCoronavirus.jsp?lingua=italiano&amp;amp;iPageNo=16#:&amp;sim;:text=22/11/2021/20CIRCOLARE/20del/20Ministero/20della/20Salute</Citation></Reference><Reference><Citation>Oliu-Barton M., Pradelski B.S.R., Woloszko N., Guetta-Jeanrenaud L., Aghion P., Artus P., Fontanet A., Martin P., Wolff G.B. The effect of COVID certificates on vaccine uptake, health outcomes, and the economy. Nature Communications. 2022;13(1):3942. doi: 10.1038/s41467-022-31394-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-31394-1</ArticleId><ArticleId IdType="pmc">PMC9263819</ArticleId><ArticleId IdType="pubmed">35803909</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., De Martino M., Fabris M., Palese A., Visintini E., Graziano E., Gerussi V., Bontempo G., D'Aurizio F., Biasotto A., Sartor A., Pipan C., Marzinotto S., Curcio F., Bouza E., Isola M., Tascini C. The fall in antibody response to SARS-CoV-2: A longitudinal study of asymptomatic to critically ill patients up to 10 Months after recovery. Journal of Clinical Microbiology. 2021;59(11) doi: 10.1128/JCM.01138-21. 21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.01138-21</ArticleId><ArticleId IdType="pmc">PMC8525561</ArticleId><ArticleId IdType="pubmed">34379530</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilz S., Theiler-Schwetz V., Trummer C., Krause R., Ioannidis J.P.A. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research. 2022;209 doi: 10.1016/j.envres.2022.112911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2022.112911</ArticleId><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Pullano G., Di Domenico L., Sabbatini C.E., Valdano E., Turbelin C., Debin M., Guerrisi C., Kengne-Kuetche C., Souty C., Hanslik T., Blanchon T., Boëlle P.-Y., Figoni J., Vaux S., Campèse C., Bernard-Stoecklin S., Colizza V. Underdetection of cases of COVID-19 in France threatens epidemic control. Nature. 2021;590(7844):134–139. doi: 10.1038/s41586-020-03095-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03095-6</ArticleId><ArticleId IdType="pubmed">33348340</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatini C.E., Pullano G., Di Domenico L., Rubrichi S., Bansal S., Colizza V. The impact of spatial connectivity on NPIs effectiveness. BMC Infectious Diseases. 2024;24(1):21. doi: 10.1186/s12879-023-08900-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08900-x</ArticleId><ArticleId IdType="pmc">PMC10763474</ArticleId><ArticleId IdType="pubmed">38166649</ArticleId></ArticleIdList></Reference><Reference><Citation>Santé publique France  CoviPrev: Une enquête pour suivre l’évolution des comportements et de la santé mentale pendant l’épidémie de COVID-19. 2020. https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19</Citation></Reference><Reference><Citation>Santé publique France  Données hospitalières relatives à l’épidémie de COVID-19. 2020. https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/</Citation></Reference><Reference><Citation>Santé publique France  Données relatives aux personnes vaccinées contre la Covid-19 (VAC-SI) 2020. https://www.data.gouv.fr/fr/datasets/donnees-relatives-aux-personnes-vaccinees-contre-la-covid-19-1/</Citation></Reference><Reference><Citation>Santé publique France  Enquêtes Flash: Évaluation de la circulation des variants du SARS-CoV-2 en France. 2022. https://www.santepubliquefrance.fr/etudes-et-enquetes/enquetes-flash-evaluation-de-la-circulation-des-variants-du-sars-cov-2-en-france</Citation></Reference><Reference><Citation>Santé publique France  Géodes—indicateurs—Campagne automne 2023. 2023. https://geodes.santepubliquefrance.fr/#c=indicator&amp;f=69&amp;i=vacsi_aut_2023_a.couv_dose&amp;s=2024-S05&amp;t=a01&amp;view=map2</Citation></Reference><Reference><Citation>Santé publique France  Consortium EMERGEN. 2023. https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/consortium-emergen</Citation></Reference><Reference><Citation>Scott L., Hsiao N., Moyo S., Singh L., Tegally H., Dor G., Maes P., Pybus O.G., Kraemer M.U.G., Semenova E., Bhatt S., Flaxman S., Faria N.R., de Oliveira T. Track Omicron's spread with molecular data. Science. 2021;374(6574):1454–1455. doi: 10.1126/science.abn4543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn4543</ArticleId><ArticleId IdType="pubmed">34882437</ArticleId></ArticleIdList></Reference><Reference><Citation>Service Public  Vaccin anti-Covid: La campagne de rappel pour les 12-17 ans s’ouvre à partir du 24 janvier 2022. 2022. https://www.service-public.fr/particuliers/actualites/A15462</Citation></Reference><Reference><Citation>Sheikh A., McMenamin J., Taylor B., Robertson C. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness. The Lancet. 2021;397(10293):2461–2462. doi: 10.1016/S0140-6736(21)01358-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01358-1</ArticleId><ArticleId IdType="pmc">PMC8201647</ArticleId><ArticleId IdType="pubmed">34139198</ArticleId></ArticleIdList></Reference><Reference><Citation>Stamm T.A., Partheymüller J., Mosor E., Ritschl V., Kritzinger S., Alunno A., Eberl J.-M. Determinants of COVID-19 vaccine fatigue. Nature Medicine. 2023:1–8. doi: 10.1038/s41591-023-02282-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02282-y</ArticleId><ArticleId IdType="pmc">PMC10202806</ArticleId><ArticleId IdType="pubmed">36973410</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein C., Nassereldine H., Sorensen R.J.D., Amlag J.O., Bisignano C., Byrne S., Castro E., Coberly K., Collins J.K., Dalos J., Daoud F., Deen A., Gakidou E., Giles J.R., Hulland E.N., Huntley B.M., Kinzel K.E., Lozano R., Mokdad A.H.…Lim S.S. Past SARS-CoV-2 infection protection against re-infection: A systematic review and meta-analysis. The Lancet. 2023;401(10379):833–842. doi: 10.1016/S0140-6736(22)02465-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Suarez Castillo M., Khaoua H., Courtejoie N. Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022. Euro Surveillance. 2022;27(16) doi: 10.2807/1560-7917.ES.2022.27.16.2200250.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.16.2200250</ArticleId><ArticleId IdType="pmc">PMC9027152</ArticleId><ArticleId IdType="pubmed">35451363</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun K., Tempia S., Kleynhans J., von Gottberg A., McMorrow M.L., Wolter N., Bhiman J.N., Moyes J., Carrim M., Martinson N.A., Kahn K., Lebina L., du Toit J.D., Mkhencele T., Viboud C., Cohen C. Rapidly shifting immunologic landscape and severity of SARS-CoV-2 in the Omicron era in South Africa. Nature Communications. 2023;14(1):246. doi: 10.1038/s41467-022-35652-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-35652-0</ArticleId><ArticleId IdType="pmc">PMC9842214</ArticleId><ArticleId IdType="pubmed">36646700</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosta S., Moreno K., Schuab G., Fonseca V., Segovia F.M.C., Kashima S., Elias M.C., Sampaio S.C., Ciccozzi M., Alcantara L.C.J., Slavov S.N., Lourenço J., Cella E., Giovanetti M. Global SARS-CoV-2 genomic surveillance: What we have learned (so far) Infection, Genetics and Evolution. 2023;108 doi: 10.1016/j.meegid.2023.105405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2023.105405</ArticleId><ArticleId IdType="pmc">PMC9847326</ArticleId><ArticleId IdType="pubmed">36681102</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzamali E., Sakkalis V., Tzedakis G., Spanakis E.G., Tzanakis N. Mathematical modeling evaluates how vaccinations affected the course of COVID-19 disease progression. Vaccines. 2023;11(4):722. doi: 10.3390/vaccines11040722.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040722</ArticleId><ArticleId IdType="pmc">PMC10142609</ArticleId><ArticleId IdType="pubmed">37112635</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Chand M., Choga W.T., Colquhoun R., Davids M., Deforche K., Doolabh D., du Plessis L., Engelbrecht S., Everatt J., Giandhari J.…de Oliveira T. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679–686. doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Vie-publique.fr  Loi du 5 août 2021 relative à la gestion de la crise sanitaire. 2021. http://www.vie-publique.fr/loi/280798-loi-5-aout-2021-vaccination-obligatoire-pass-sanitaire-crise-covid-19 vie-publique.fr.</Citation></Reference><Reference><Citation>Vie-publique.fr  Interview de M. Jean Castex, Premier ministre, à RTL le 26 août 2021, sur le protocole sanitaire pour la rentrée scolaire, les vaccinations, la situation économique, la politique de réformes et l’accueil de réfugiés afghans en France. 2021. https://www.vie-publique.fr/discours/281305-castex-26082021-rentree-scolaire-covid-vaccinations-accueil-afghans vie-publique.fr.</Citation></Reference><Reference><Citation>Wang H., Ibuka Y., Nakamura R. Mixing age and risk groups for accessing COVID-19 vaccines: A modelling study. BMJ Open. 2022;12(12) doi: 10.1136/bmjopen-2022-061139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-061139</ArticleId><ArticleId IdType="pmc">PMC9748520</ArticleId><ArticleId IdType="pubmed">36523241</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. 2021. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern</Citation></Reference><Reference><Citation>WHO  Ending the COVID-19 emergency and transitioning from emergency phase to longer-term disease management: Guidance on calibrating the response, 4 September 2023. 2023. https://www.who.int/publications-detail-redirect/WHO-WHE-SPP-2023.2</Citation></Reference><Reference><Citation>WHO  Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 2023. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic</Citation></Reference><Reference><Citation>WHO  Roadmap on uses of COVID-19 vaccines in the context of Omicron and high population immunity. 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2023.2</Citation></Reference><Reference><Citation>WHO  Respiratory infectious diseases on the rise across WHO European Region. 2023. https://www.who.int/europe/news/item/15-12-2023-respiratory-infectious-diseases-on-the-rise-across-who-european-region</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>